ReviewReviews in medical virology2021
Transplantation in the era of the Covid-19 pandemic: How should transplant patients and programs be handled?
Review in Reviews in medical virology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 17 citations in OpenAlex.
- Severe COVID-19-related Pneumonia Seven Years after Heart Transplantation.Internal medicine (Tokyo, Japan) · 2025Article
- Optimized tacrolimus dosing strategy in kidney transplant recipients receiving nirmatrelvir-ritonavir for COVID-19.PloS one · 2025Observational
- Impact of COVID-19 pandemic on care of maintenance hemodialysis patients: a multicenter study.Clinical and experimental nephrology · 2024Observational
- Outcomes of Patients Receiving a Kidney Transplant or Remaining on the Transplant Waiting List at the Epicentre of the COVID-19 Pandemic in Europe: An Observational Comparative Study.Pathogens (Basel, Switzerland) · 2022Article
- Strategies to Mitigate the Impact of COVID 19 Pandemic on Organ Donation and Kidney Transplantation in Latin America.Current urology reports · 2021Review
- Immunosuppression in kidney transplant recipients with COVID-19 infection - where do we stand and where are we heading?Renal failure · 2021Review
- COVID-19 and Indirect Liver Injury: A Narrative Synthesis of the Evidence.Journal of clinical and translational hepatology · 2021Review
- A review of the evidence for and against the use of steroids in renal transplant patients with COVID-19.Saudi medical journal · 2021Article
- Kidney Transplantation in COVID Pandemic-A Review of Guidelines.Journal of clinical medicine · 2021Review
- Early detection of SARS-CoV-2 and other infections in solid organ transplant recipients and household members using wearable devices.Transplant international : official journal of the European Society for Organ Transplantation · 2021Review
- Successful Management of COVID-19 Infection in 2 Early Post-Liver Transplant Recipients.Transplantation proceedings · 2021Article
- Comprehensive Immune Profiling of a Kidney Transplant Recipient With Peri-Operative SARS-CoV-2 Infection: A Case Report.Frontiers in immunology · 2021Article
- Transplantation in the era of the Covid-19 pandemic: How should transplant patients and programs be handled?Reviews in medical virology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Due to the Covid-19 pandemic caused by SARS-CoV-2, transplant programs worldwide have been severely impacted with dwindling numbers of transplantations performed and a complete halt in several areas. In this review we examine whether SARS-CoV-2 infection presents differently in transplant recipients, whom and how we should test, how susceptible the transplant population is to overt infection and describe the range of outcomes. From retrieved published reports on SARS-CoV-2infections in 389solid organ transplant recipients reported in the literature, the overall mortality rate was 16.7% (n = 65); however for those with mild or moderate Covid-19 disease this was 2.9% and 2.3% respectively; conversely, for those with severe infection the mortality rate was 52.2%.We then address questions regarding halting transplantation programs during this pandemic, whether all human tissues being considered for transplantation are capable of transmitting the infection, and if we should alter immunosuppressive medications during the pandemic.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.